W H Matsui

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint The role of growth factors in the activity of pharmacological differentiation agents
    William H Matsui
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Cell Growth Differ 13:275-83. 2002
  2. ncbi request reprint Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes
    W H Matsui
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leukemia 20:458-62. 2006
  3. ncbi request reprint Strategies to eliminate cancer stem cells: clinical implications
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231, USA
    Eur J Cancer 42:1293-7. 2006
  4. pmc Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
    William Matsui
    The Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 68:190-7. 2008
  5. pmc Autologous stem cell transplantation and multiple myeloma cancer stem cells
    William Matsui
    The Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Division of Hematologic Malignancies, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Biol Blood Marrow Transplant 18:S27-32. 2012
  6. pmc Concise review: Emerging concepts in clinical targeting of cancer stem cells
    Zeshaan A Rasheed
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Stem Cells 29:883-7. 2011
  7. pmc Characterization of clonogenic multiple myeloma cells
    William Matsui
    Sidney Kimmel Comprehensive Cancer Center, John Hopkins University School of Medicine, Bunting Blaustein Cancer Research Bldg, Rm 245, 1650 Orleans St, Baltimore, MD 21231, USA
    Blood 103:2332-6. 2004
  8. ncbi request reprint Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation
    William Matsui
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Br J Haematol 121:251-8. 2003
  9. ncbi request reprint Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia
    William Matsui
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Br J Haematol 128:853-62. 2005
  10. pmc Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma
    Zeshaan A Rasheed
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Natl Cancer Inst 102:340-51. 2010

Research Grants

  1. Biology of Multiple Myeloma Stem Cells
    William Matsui; Fiscal Year: 2007
  2. Cancer Stem Cell Targeting in Multiple Myeloma
    William Matsui; Fiscal Year: 2009
  3. Cancer Stem Cell Targeting in Multiple Myeloma
    William H Matsui; Fiscal Year: 2010
  4. Cancer Stem Cell Targeting in Multiple Myeloma
    William Matsui; Fiscal Year: 2009

Collaborators

Detail Information

Publications46

  1. ncbi request reprint The role of growth factors in the activity of pharmacological differentiation agents
    William H Matsui
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Cell Growth Differ 13:275-83. 2002
    ..These data suggest that many pharmacological differentiating agents require both cell cycle arrest and lineage-specific growth factors for full activity and may explain why these agents have demonstrated only limited clinical efficacy...
  2. ncbi request reprint Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes
    W H Matsui
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leukemia 20:458-62. 2006
    ..Quantification of marrow CD34+ cells may serve as an important tool for distinguishing between AA and hMDS...
  3. ncbi request reprint Strategies to eliminate cancer stem cells: clinical implications
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231, USA
    Eur J Cancer 42:1293-7. 2006
    ..Re-examining both our pre-clinical and clinical drug development paradigms to include the cancer stem cell concept has the potential to revolutionize the treatment of many cancers...
  4. pmc Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
    William Matsui
    The Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 68:190-7. 2008
    ..Our results suggest that circulating clonotypic B-cell populations represent multiple myeloma stem cells, and the relative drug resistance of these cells is mediated by processes that protect normal stem cells from toxic injury...
  5. pmc Autologous stem cell transplantation and multiple myeloma cancer stem cells
    William Matsui
    The Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Division of Hematologic Malignancies, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Biol Blood Marrow Transplant 18:S27-32. 2012
    ..Putative CSCs have been identified in MM, and their characterization may lead to the development of novel maintenance strategies that inhibit the production of new tumor cells, prevent disease relapse, and improve overall survival...
  6. pmc Concise review: Emerging concepts in clinical targeting of cancer stem cells
    Zeshaan A Rasheed
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Stem Cells 29:883-7. 2011
    ..We will review current evidence supporting the role of CSCs in clinical oncology and discuss potential barriers and strategies in designing trials examining CSC-targeting agents...
  7. pmc Characterization of clonogenic multiple myeloma cells
    William Matsui
    Sidney Kimmel Comprehensive Cancer Center, John Hopkins University School of Medicine, Bunting Blaustein Cancer Research Bldg, Rm 245, 1650 Orleans St, Baltimore, MD 21231, USA
    Blood 103:2332-6. 2004
    ..These data suggest that MM "stem cells" are CD138- B cells with the ability to replicate and subsequently differentiate into malignant CD138+ plasma cells...
  8. ncbi request reprint Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation
    William Matsui
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Br J Haematol 121:251-8. 2003
    ..These results suggest that the differentiating activities of IFN-alpha may play a role in its clinical antimyeloma activity and provide the rationale for clinical differentiation therapy in MM...
  9. ncbi request reprint Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia
    William Matsui
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Br J Haematol 128:853-62. 2005
    ..The combined use of pharmacologic differentiating agents and growth factors may improve the clinical efficacy of differentiation therapy in APL...
  10. pmc Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma
    Zeshaan A Rasheed
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Natl Cancer Inst 102:340-51. 2010
    ..Aldehyde dehydrogenase (ALDH) activity can identify tumor-initiating cells and normal stem cells from several human tissues. We examined the prognostic significance and functional features of ALDH expression in pancreatic adenocarcinoma...
  11. ncbi request reprint Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors
    Kimberly Noonan
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Cancer Res 65:2026-34. 2005
    ..Taken together, these results highlight the intrinsic tumor specificity of MILs and describe a novel approach for the generation of tumor-specific T-cell populations suitable for adoptive immunotherapy of multiple myeloma...
  12. pmc DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation
    Peng Sun
    Department of Neurology, The Johns Hopkins University School of Medicine and The Hugo W Moser Research Institute at Kennedy Krieger, Baltimore, Maryland 21205, USA
    Stem Cells 27:1473-86. 2009
    ..Our findings are the first to implicate noncanonical Notch signaling in the regulation of neoplastic stem-like cells and suggest novel neoplastic stem cell targeting treatment strategies for GBM and potentially other solid malignancies...
  13. pmc HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 14:641-50. 2008
    ..02). Nonmyeloablative HLA-haploidentical BMT with posttransplantation Cy is associated with acceptable rates of fatal graft failure and severe aGVHD or cGVHD...
  14. pmc Urothelial carcinoma: stem cells on the edge
    William D Brandt
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Cancer Metastasis Rev 28:291-304. 2009
    ..In this review, we discuss the implications of these findings in understanding CSCs and in better understanding how UroCas form, progress, and should be treated...
  15. pmc Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma
    Craig D Peacock
    Sidney Kimmel Comprehensive Cancer Center and Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 104:4048-53. 2007
    ..The potential existence of similar relationships in other adult cancers may have important biologic and clinical implications for the study of aberrant Hh signaling...
  16. pmc Mantle cell lymphoma activation enhances bortezomib sensitivity
    Sarah K Brennan
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Blood 116:4185-91. 2010
    ..Our data suggest that CpG may target clonogenic and resistant ALDH(+) cells as well as improve the activity of proteasome inhibitors in MCL...
  17. pmc Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors
    Akil Merchant
    The Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Blood 115:2391-6. 2010
    ..Moreover, they suggest that Gli1 and Smoothened may not be functionally redundant, and direct GLI1 inhibitors may be needed to effectively block HH/GLI1 activity in human disease...
  18. pmc Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma
    Eli E Bar
    Johns Hopkins University School of Medicine, Department of Pathology, 720 Rutland Avenue, Ross Building 558, Baltimore, Maryland 21205, USA
    Stem Cells 25:2524-33. 2007
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  19. pmc Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma
    Javier BolaƱos-Meade
    George W Santos Bone Marrow Transplant Service, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Biol Blood Marrow Transplant 13:1185-91. 2007
    ..The administration of oral cyclosporine followed by interleukin-2 and gamma-interferon is generally not well tolerated, and does not appear to be an effective method to induce autologous GVHD in patients receiving autologous PBSC grafts...
  20. pmc Characterization of chronic myeloid leukemia stem cells
    Jonathan M Gerber
    Division of Hematology, Department of Medicine, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Am J Hematol 86:31-7. 2011
    ..These expression patterns suggest that PROTEINASE 3, SURVIVIN, and hTERT are not optimal therapeutic targets in CML stem cells; whereas PRAME and WT1 seem promising...
  21. pmc Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer
    Tianyun Jiang
    Departments of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 69:845-54. 2009
    ..Intrinsic tumor cell heterogeneity, including variation in key regulatory factors such as ASCL1, can modulate tumorigenicity in SCLC...
  22. pmc A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development
    Antonio Jimeno
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231 1000, USA
    Mol Cancer Ther 8:310-4. 2009
    ..Direct tumor xenografts are a valid platform to test multicompartment therapeutic approaches in pancreatic cancer...
  23. pmc The paradox of response and survival in cancer therapeutics
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Blood 107:431-4. 2006
    ..In this article, we discuss the evidence for cancer stem cells in hematologic malignancies and possible ways to begin targeting these cells and measuring clinical effectiveness of such treatment approaches...
  24. pmc Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres
    Eli E Bar
    Johns Hopkins University School of Medicine, Department of Pathology, Baltimore, MD 21287, USA
    Am J Pathol 177:1491-502. 2010
    ....
  25. pmc High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Blood 115:3224-30. 2010
    ..These results suggest that high-dose posttransplantation cyclophosphamide is an effective single-agent prophylaxis of acute and chronic GVHD after BuCy conditioning and HLA-matched BMT (clinicaltrials.gov no. NCT00134017)...
  26. pmc An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer
    Georg Feldmann
    Department of Pathology, Johns Hopkins University School of Medicine, CRB2, Room 316, 1550 Orleans Street, Baltimore, MD 21231, USA
    Mol Cancer Ther 7:2725-35. 2008
    ....
  27. pmc Multiple myeloma cancer stem cells
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, CRB245, 1650 Orleans St, Baltimore, MD 21231, USA
    J Clin Oncol 26:2895-900. 2008
    ..We review evidence that functional heterogeneity exists in multiple myeloma and discuss potential strategies and clinical implications of the stem-cell model of cancer in this disease...
  28. ncbi request reprint Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors
    Xing Fan
    Department of Pathology, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205, USA
    Cancer Res 66:7445-52. 2006
    ..Stem-like cells in brain tumors thus seem to be selectively vulnerable to agents inhibiting the Notch pathway...
  29. pmc Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers
    Georg Feldmann
    Department of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, MD 21231, USA
    Cancer Res 67:2187-96. 2007
    ....
  30. pmc Circulating clonotypic B cells in classic Hodgkin lymphoma
    Richard J Jones
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Blood 113:5920-6. 2009
    ..Although the clinical significance of circulating clonotypic B cells in HL remains unclear, these data suggest they may be the initiating cells for HL...
  31. pmc The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity
    Josh Lauring
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Department of Chemical and Biomolecular Engineering, Baltimore, MD 21231, USA
    Blood 111:856-64. 2008
    ..These results provide the first direct evidence that MMSET plays a significant role in t(4;14) MM and suggest that therapies targeting this gene could impact this particular subset of poor-prognosis patients...
  32. pmc Higher serum folate levels are associated with a lower risk of atopy and wheeze
    Elizabeth C Matsui
    Division of Pediatric Allergy and Immunology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
    J Allergy Clin Immunol 123:1253-9.e2. 2009
    ..Folic acid is known to be associated with inflammatory diseases, but the relationship between folic acid and allergic diseases is unclear...
  33. pmc Cancer stem cells in multiple myeloma
    Nilanjan Ghosh
    Division of Hematologic Malignancies, Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA
    Cancer Lett 277:1-7. 2009
    ..We review studies that have examined clonogenic cells in multiple myeloma, highlight controversies regarding the cell of origin in multiple myeloma, and discuss potential targeting strategies...
  34. pmc Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen
    J Bolanos-Meade
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Bone Marrow Transplant 43:477-80. 2009
    ..The combination of fludarabine and alemtuzumab is an effective and well-tolerated salvage conditioning regimen for patients who experience graft failure after blood or marrow transplants...
  35. pmc Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer
    Michael E Mullendore
    Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Cancer Res 15:2291-301. 2009
    ..Aberrant activation of the Notch signaling pathway is commonly observed in human pancreatic cancer, although the mechanism(s) for this activation has not been elucidated...
  36. pmc Targeting Hedgehog--a cancer stem cell pathway
    Akil A Merchant
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Clin Cancer Res 16:3130-40. 2010
    ..The diverse nature of Hh signaling in human cancers suggests that disease-specific factors must be carefully considered to identify the optimal use of novel pathway inhibitors...
  37. pmc Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells
    Joyce E Ohm
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 70:7662-73. 2010
    ..Our findings suggest that by studying the process of induced reprogramming, we may gain significant insight into the origins of epigenetic gene silencing associated with human tumorigenesis, and add to means of assessing iPS for safety...
  38. pmc Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis
    Jasmin Roya Agarwal
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Anticancer Agents Med Chem 10:116-20. 2010
    ..Here we review the identification and characterization of MM CSCs, the role of Hh in MM, and issues to be considered during the early clinical testing of CSC targeting agents...
  39. pmc Cancer stem cells: controversies in multiple myeloma
    Sarah K Brennan
    Division of Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA
    J Mol Med (Berl) 87:1079-85. 2009
    ..Moreover, we speculate how these inconsistencies may be resolved through studies by integrating advancements in both myeloma and stem cell biology...
  40. pmc Therapeutic implications of leukemic stem cell pathways
    Saranya Chumsri
    Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, USA
    Clin Cancer Res 13:6549-54. 2007
    ..The translation of novel and existing leukemic stem cell-directed therapies into clinical practice, however, will require changes in clinical trial design and the inclusion of stem cell biomarkers as correlative end points...
  41. pmc Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH
    William J Savage
    Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 2196, USA
    Exp Hematol 37:42-51. 2009
    ..Investigate the contribution of PIG-A mutations to clonal expansion in paroxysmal nocturnal hemoglobinuria (PNH)...
  42. doi request reprint Smoothening the controversial role of hedgehog in hematopoiesis
    Akil A Merchant
    Division of Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231, USA
    Cell Stem Cell 4:470-1. 2009
    ..In this issue of Cell Stem Cell, two separate reports (Hofmann et al., 2009; Gao et al., 2009) examine whether the Hedgehog signaling pathway modulates normal adult hematopoietic stem cells and blood formation...
  43. ncbi request reprint Cancer stem cells: are we missing the target?
    Richard J Jones
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Natl Cancer Inst 96:583-5. 2004
  44. ncbi request reprint Enhanced cytotoxicity of rituximab following genetic and biochemical disruption of glycosylphosphatidylinositol anchored proteins
    Nagaprasad Nagajothi
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Leuk Lymphoma 45:795-9. 2004
    ..Thus, genetic and biochemical interruption of GPI anchor proteins augments sensitivity to rituximab...
  45. ncbi request reprint Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 12:414-21. 2006
    ..However, with the exception of CML, most patients die of their underlying disease because of insufficient antitumor activity even with active GVHD...
  46. ncbi request reprint Association of Foxp3 regulatory gene expression with graft-versus-host disease
    Yuji Miura
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Blood 104:2187-93. 2004
    ..The decrease in regulatory mechanisms after transplantation appears to provide an environment permissive to the development of GVHD...

Research Grants6

  1. Biology of Multiple Myeloma Stem Cells
    William Matsui; Fiscal Year: 2007
    ..Both clinical outcomes and laboratory correlates will be integrated to serve as the foundation for the development of subsequent generations of clinical trials. ..
  2. Cancer Stem Cell Targeting in Multiple Myeloma
    William Matsui; Fiscal Year: 2009
    ....
  3. Cancer Stem Cell Targeting in Multiple Myeloma
    William H Matsui; Fiscal Year: 2010
    ....
  4. Cancer Stem Cell Targeting in Multiple Myeloma
    William Matsui; Fiscal Year: 2009
    ..abstract_text> ..